ERS Genomics signs CRISPR patent deal on industrial applications

ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

ERS Genomics licenses CRISPR patents to Cambridge University spin-out

1 November 2018 The company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, ERS Genomics, has signed a patent licensing deal with DefiniGEN, a spin-out from the University of Cambridge, UK.

Americas

ERS extends CRISPR influence with two licensing deals

20 September 2018 ERS Genomics and the Broad Institute of MIT and Harvard signed CRISPR licensing deals with Thermo Fisher Scientific on Tuesday, shortly before ERS expanded a separate agreement with Oxford Genetics.

Europe

EPO grants second CRISPR patent to ERS Genomics

7 March 2018 The European Patent Office has granted a second CRISPR/Cas9 patent to a specialist genomics company, one month after revoking the Broad Institute of Harvard and MIT’s patent relating to the technology.